Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Washington D.C., District of Columbia

Phase 3 cancer trials in Washington D.C., DC

58 Phase 3 cancer studies are recruiting participants at sites in Washington D.C. as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Washington D.C. at a glance

  • 58 studies are recruiting at a site in Washington D.C..
  • By phase: Phase 2/3 (6), Phase 3 (52).
  • By sponsor: industry (33), university, hospital or other (18), government (7).
  • By research area: Lung Cancer (17), Breast Cancer (16), Lymphoma (9), Prostate Cancer (8), Melanoma (4), Pancreatic Cancer (4).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Washington D.C.

Basic details from each study's public record (the 30 most recently updated of 58). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington Hospital Center ( Site 0098)
    Registry record
    NCT06841354 · updated
  2. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Georgetown Uni Hospital
    Registry record
    NCT05894239 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06058377 · updated
  4. A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Genentech, Inc.
    Study site
    MedStar Washington Hospital Center
    Registry record
    NCT07541079 · updated
  5. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    Georgetown University Medical Center
    Registry record
    NCT06982521 · updated
  6. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study sites
    MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT05633654 · updated
  7. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    George Washington University Medical Center · Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital
    Registry record
    NCT05879926 · updated
  8. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT06748222 · updated
  9. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    MedStar Washington Hospital Center
    Registry record
    NCT07174336 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Lung cancer studies recruiting in Washington D.C.

  1. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington Hospital Center ( Site 0037)
    Registry record
    NCT06422143 · updated
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kaiser Permanente-Capitol Hill Medical Center · MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT04267848 · updated
  3. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    George Washington University Medical Center
    Registry record
    NCT06096844 · updated
  4. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    OSE Immunotherapeutics
    Study site
    Georgetown Lombardi Comprehensive Cancer Center
    Registry record
    NCT06472245 · updated
  5. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Washington DC Veterans Affairs Medical Center
    Registry record
    NCT06758401 · updated
  6. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    George Washington University Medical Center
    Registry record
    NCT04181060 · updated
  7. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06119581 · updated
  8. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06890598 · updated
  9. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study sites
    MEDSTAR Washington Hospital Center (MedStar Health Research Institute) · MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)
    Registry record
    NCT06712316 · updated
  10. A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Takeda
    Study site
    MedStar Georgetown Cancer Institute-Oncology Research
    Registry record
    NCT07217301 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Prostate cancer studies recruiting in Washington D.C.

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT04423211 · updated
  2. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    MedStar Georgetown University Hospital · MedStar Washington Hospital Center
    Registry record
    NCT06931340 · updated
  3. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
    Registry record
    NCT07164443 · updated
  4. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Washington DC Veterans Affairs Medical Center ( Site 0056)
    Registry record
    NCT06925737 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Lymphoma studies recruiting in Washington D.C.

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06337318 · updated
  2. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT06724237 · updated
  3. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Sibley Memorial Hospital
    Registry record
    NCT04269902 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's National Medical Center · MedStar Georgetown University Hospital
    Registry record
    NCT05675410 · updated
  5. A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Georgetown University
    Registry record
    NCT06084936 · updated
  6. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    MedStar Georgetown University Hospital
    Registry record
    NCT07188558 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Washington D.C.

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US013
    Registry record
    NCT07522073 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.

Ask about studies near Washington D.C.

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call